Okanagan Clinical Trials press release
Celiac Disease is an autoimmune disorder, which damages the small intestine and affects its ability to absorb nutrients from food. Currently, the only management available for this condition is strict adherence to a gluten-free diet – in which all products with wheat or a variety of other grains are off limits.
“Avoiding gluten is very difficult for patients and having to live on a gluten-free diet is restrictive and can definitely affect your quality of life,” says Dr. Sally Godsell, investigator for Okanagan Clinical Trials. “If it is possible to develop a new medicine for this condition, which could help patients reduce their signs and symptoms, it would make a big difference for a lot of people.”
Celiac Disease affects 1% of the population or about ~346,890 people in Canada, ~3 million people in the United States and it occurs in individuals who are genetically susceptible. Gluten, a protein found in grains such as wheat, rye and barley, triggers an immune response in the body that damages the mucosal lining of the small intestine.
If left unmanaged, Celiac Disease can cause chronic intestinal damage and increased risk for a variety of disorders included iron deficiency anemia, osteoporosis, vitamin deficiencies, nervous system disorders, pancreatic insufficiency, lactose intolerance, intestinal lymphomas and other gastrointestinal cancers.
The current research study at Okanagan Clinical Trials is examining an investigational medication that is now being tested for its effectiveness and tolerability in Celiac Disease.
In order to meet research study criteria, volunteers must be between the ages of 18 and 75, and diagnosed with Celiac Disease by biopsy and blood test 12 months or more before research study entry. Volunteers must also have attempted a gluten-free diet for 12 months or longer and are still experiencing gastrointestinal symptoms when exposed to gluten.
More than 320 patients at 60 centers across the United States and Canada will participate in this research study. Okanagan Clinical Trials was selected to participate because of its proven track record in conducting clinical trials since 1992.
Effects will be measured over a 20 week period and will not affect regular medical coverage. Participants are free to leave the research study at any time.
For more information see: Celiac Disease Clinical Trial Invitation Letter
or visit www.okanaganclinicaltrials.com